Heroic-Faith Medical Science Co., Ltd.
Frank Wu, one of the founders of Heroic-Faith Medical Science and Raising Children Healthcare Foundation, believes in innovative technology as a methodology of assisting future clinical solutions. Mr. Wu together with Dr. Fushun Hsu, critical care doctor, strives to improve the current healthcare obstacle from both the aspect of clinical practice and innovative knowledge. Based on the belief of saving more lives through the holistic understanding of our health. Heroic-Faith puts innovation in the right place to make our world a healthier and better place.
Hsinchu Science Park
AI, Healthcare, MedTech
"An introduction to the Hsinchu Science Park
Hsinchu Science ParkIn 1951, Stanford University started the world’s first science park, which would later come to be known as Silicon Valley. Similar establishments have proliferated rapidly throughout the world ever since—there are now more than 100 science parks globally. In addition to being in different stages of development, these parks differ from one another in their modes of management and structure due to the diversity of social conventions, cultural backgrounds and economic prowess involved. Science parks in the U.S. are mainly a market-economy product, which is hardly a surprise given the country’s longstanding belief in laissez faire. In contrast, most science parks in East Asia tend to be dictated by government planning as authoritarianism is often the prevailing political doctrine in the region. Even in the same country, it is not uncommon for one science park to differ from the next one in terms of their management modes. Silicon Valley, for instance, is primarily what people will expect of a market economy, but the Research Triangle Park in North Carolina is readily recognizable as an entity subject to government intervention. Furthermore, what these establishments are called also differ from country to country; their names include science park, science-based industrial park, science and technology park, science city, etc."
i-Navi Biomedical Inc.
i-Navi Biomedical Inc., founded by Prof. Ching Shiow Tseng and his team members with more than 20-years’ experience in surgical navigation system development, is a company specialized in developing image-assisted/robotic surgical navigation systems for neurosurgery and orthopedic surgery. The 2D/3D C-arm or CT/CTA/MRI images based i-Navi robotic surgical navigation system (robot is an option) for spine/brain surgery enables surgeons to accurately and efficiently position surgical instruments and implants during operations. Using the i-Navi navigation system in minimally invasive spine/brain surgery can significantly reduce X-ray radiation exposure, improve positioning accuracy and surgical risk, and even reduce operation time. Clinical applications of the input image assisted navigation system have been tested and validated at Cathy General Hospital and Tao-Yuan General Hospital. Filing applications for FDA/TFDA approval will be done in one year. The company's goal aims to develop advanced robotic surgical systems to assist medical treatments and improve patients' health. Integration of new technologies such as AI, AR/MR into i-Navi systems to enhance system functions and capabilities is in progress.
Singular Wings Medical
MedTech, Healthcare, IoT, AI, ICT
Singular Wings Medical Co., Ltd. focus on health care and medical device including hardware design, software development and clouds platform services. Our products and services can be widely applied on resident care, disease care, health management, fitness, competitions, training, sports and other applications. We develop wearable devices which detect physiological signal and combine with smart watches, smart clothing, palm-type measurement device, etc.
Taiwan RedEye Biomedical Inc.
Taiwan RedEye Biomedical Inc. is a start-up company from Hsinchu, Taiwan. RedEye contributes to doing the research and development on device which can detect if there is any trace of blood hidden in the excrement. Our goal is to help people find the initial symptoms of colorectal cancer, kidney disease, and bladder cancer and to be aware of the situation of inflammation throughout the body in order to realize home health monitoring. Doing well on daily health management can achieve the goal of early detection and early treatment. RedEye’s R&D center is in Taiwan. Our manufacturing base is in Taiwan and China, and we view the whole world as our stages and markets.
Instant NanoBiosensors Co., Ltd
Taiwan-based Instant NanoBiosensors (INB) is a pioneer that specializes in light-sensing biosensor platform development. The mission of the company’s dynamic and problem-driven R&D team is to advance biomedical research and improve patient care by providing customers with simple, reliable, and cost-effective solutions. Its state-of-the-art fiberoptic particle plasmon resonance (FOPPR) technology offers instant and accurate results for a wide range of detection applications. By combining novel biomarkers with a cutting-edge biosensing platform, INB aspires to revolutionize traditional immunoassays and analyses for a more efficient healthcare ecosystem.
We apply microfluidics as our core technique to develop an in vitro diagnostic (IVD) system to support the precision medicine of antibiotics. Targeting the emergence of antimicrobial resistance (AMR) which is literally one of the ten threats to the global health in 2019 according to WHO. Our system, fAST, can carry out rapid bacteria identification within 1.5 hours, following by a multiple antibiotics combination test within 5 hours. To conclude, we are the fastest and first-in-class system in the market that can optimize three different kind of antibiotics combination to provide clinicians with accurate and personalized results.
BRAXX Biotech Co., Ltd.
BRAXX focuses on developing innovative medical device for radiation therapy with precise positioning. BRAXX aims to improve the therapeutic efficacy and avoids the side effects in traditional brachytherapy procedures. The esophageal brachytherapy applicator provides cancer patients a new treatment option.